Vera Therapeutics Inc (VERA)
43.47
+1.16
(+2.74%)
USD |
NASDAQ |
May 02, 16:00
43.00
-0.47
(-1.08%)
After-Hours: 20:00
Vera Therapeutics Enterprise Value: 2.193B for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 2.193B |
| April 30, 2024 | 2.041B |
| April 29, 2024 | 2.142B |
| April 26, 2024 | 2.048B |
| April 25, 2024 | 1.996B |
| April 24, 2024 | 2.065B |
| April 23, 2024 | 2.041B |
| April 22, 2024 | 2.020B |
| April 19, 2024 | 1.958B |
| April 18, 2024 | 2.039B |
| April 17, 2024 | 2.068B |
| April 16, 2024 | 2.207B |
| April 15, 2024 | 2.423B |
| April 12, 2024 | 2.501B |
| April 11, 2024 | 2.548B |
| April 10, 2024 | 2.155B |
| April 09, 2024 | 1.953B |
| April 08, 2024 | 1.993B |
| April 05, 2024 | 1.932B |
| April 04, 2024 | 1.926B |
| April 03, 2024 | 2.045B |
| April 02, 2024 | 2.114B |
| April 01, 2024 | 2.195B |
| March 28, 2024 | 2.237B |
| March 27, 2024 | 2.276B |
| Date | Value |
|---|---|
| March 26, 2024 | 2.153B |
| March 25, 2024 | 2.131B |
| March 22, 2024 | 2.122B |
| March 21, 2024 | 2.224B |
| March 20, 2024 | 2.357B |
| March 19, 2024 | 2.253B |
| March 18, 2024 | 2.147B |
| March 15, 2024 | 2.212B |
| March 14, 2024 | 2.225B |
| March 13, 2024 | 2.318B |
| March 12, 2024 | 2.262B |
| March 11, 2024 | 2.208B |
| March 08, 2024 | 2.268B |
| March 07, 2024 | 2.215B |
| March 06, 2024 | 2.353B |
| March 05, 2024 | 2.314B |
| March 04, 2024 | 2.389B |
| March 01, 2024 | 2.528B |
| February 29, 2024 | 2.418B |
| February 28, 2024 | 2.356B |
| February 27, 2024 | 2.475B |
| February 26, 2024 | 2.378B |
| February 23, 2024 | 2.438B |
| February 22, 2024 | 2.521B |
| February 21, 2024 | 2.282B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
60.56M
Minimum
Jan 09 2023
2.548B
Maximum
Apr 11 2024
530.24M
Average
382.05M
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 92.67B |
| Alpine Immune Sciences Inc | 3.908B |
| Fate Therapeutics Inc | 90.71M |
| Checkpoint Therapeutics Inc | 44.68M |
| Mersana Therapeutics Inc | 224.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.66M |
| Total Expenses (Quarterly) | 27.03M |
| EPS Diluted (Quarterly) | -0.58 |
| Earnings Yield | -5.27% |